open_in_newOriginal article
Tech Mahindra, Wipro Individually Partner With NVIDIA at GTC 2025

Tech Mahindra, Wipro Individually Partner With NVIDIA at GTC 2025

  • 19.03.2025 14:44
  • analyticsindiamag.com
  • Keywords: AI

Tech Mahindra and Wipro have separately partnered with NVIDIA to advance AI-driven solutions. Tech Mahindra is collaborating on an autonomous pharmacovigilance system using NVIDIA AI Enterprise software for drug safety, while Wipro is developing country-specific AI solutions across industries like healthcare and banking.

Nvidia ServicesNVDAsentiment_satisfiedWITsentiment_satisfied

Estimated market influence

Tech Mahindra

Positivesentiment_satisfied
Analyst rating: N/A

Collaboration with NVIDIA to develop AI-based pharmacovigilance solution, enhancing drug safety management.

NVIDIA

NVIDIA

Positivesentiment_satisfied
Analyst rating: Strong buy

Partnership with Tech Mahindra and Wipro to advance AI solutions in healthcare and other sectors.

Wipro

Wipro

Positivesentiment_satisfied
Analyst rating: Neutral

Collaboration with NVIDIA for AI solutions tailored to local needs, enhancing various industries' efficiency.

Context

Analysis and Summary: Tech Mahindra and Wipro Partnering with NVIDIA at GTC 2025

Key Collaborations

  • Tech Mahindra & NVIDIA: Developing an autonomous pharmacovigilance solution using:

    • Tech Mahindra’s TENO framework
    • NVIDIA AI Enterprise software (NeMo, NIM microservices, AI Blueprints)

  • Wipro & NVIDIA: Partnering to develop country-specific AI solutions using:

    • Wipro’s WeGA Studio
    • NVIDIA AI software

Market Impact and Benefits

  • Pharmacovigilance Solution:

    • Reduces human error in drug safety management.
    • Automates workflows for case intake, data transformation, quality control, and compliance.
    • AI agents classify, prioritize, and verify pharmacovigilance emails.

  • Performance Metrics:

    • Turnaround time reduction: up to 40%
    • Data accuracy improvement: 30%
    • Operational cost reduction: 25%

Industry Implications

  • AI in Healthcare: AI is becoming critical for monitoring medicines throughout their lifecycle, enhancing safety and compliance.
  • Regulatory Compliance: The solution supports autonomous decision-making for adverse drug reaction (ADR) cases and regulatory compliance.

Competitive Dynamics

  • Tech Mahindra’s Positioning: Strengthening its role as a leader in pharma AI solutions with NVIDIA collaboration.
  • Wipro’s Expansion: Leveraging NVIDIA tools to develop localized AI solutions across industries like healthcare, banking, education, and emergency services.

Strategic Considerations

  • Customer Impact: Improved efficiency in managing large volumes of data for global pharmaceutical customers.
  • Innovation Focus: Application of generative AI and multi-agent systems to revolutionize drug safety management.

Long-Term Effects

  • Potential expansion into multiple use cases beyond pharmacovigilance, leveraging NVIDIA’s AI-driven framework.
  • Enhanced data security and sovereignty through localized AI solutions.

Quotes from Leaders

  • John Fanelli (NVIDIA): "AI is ideal for monitoring medicines throughout their lifecycle to support safety."
  • Anant Malhotra (Tech Mahindra): "Together, we are revolutionising drug safety management."

Conclusion

The partnerships with NVIDIA position Tech Mahindra and Wipro as pioneers in AI-driven healthcare solutions, with significant implications for improving drug safety, reducing costs, and enhancing regulatory compliance.